Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?
Fiche publication
Date publication
décembre 2014
Journal
Expert review of clinical immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Lopez A, Beaugerie L, Peyrin-Biroulet L
Lien Pubmed
Résumé
Thiopurines remain the backbone therapy of inflammatory bowel diseases (IBD). However, these drugs have potential mutagenic and carcinogenic effects, especially when prescribed for a long time. In addition to the increased risk of lymphoma and non-melanoma skin cancer, recent data suggest that risk of myeloid disorder is increased in IBD patients with past exposure to thiopurines. Even if individual risk is low, practitioners who take care of IBD patients should be aware of this potential complication of thiopurines treatment.
Mots clés
Anti-Inflammatory Agents, adverse effects, Humans, Inflammatory Bowel Diseases, drug therapy, Leukemia, chemically induced, Myelodysplastic Syndromes, chemically induced, Purines, adverse effects
Référence
Expert Rev Clin Immunol. 2014 Dec;10(12):1563-5